Four Local Women Pool Talents to Launch ‘ReSet Lounge’ in Chagrin Falls
Chagrin Falls, Ohio (Issued August 2020) -- During 2019, four women – mothers to a total of 11 – decided there was something missing in their otherwise idyllic Village of Chagrin Falls, a suburb of Cleveland, Ohio.
“We’re fortunate to live in such a peaceful place,” says co-founder Beth Johnson, “but we realized that families everywhere, at some point in their lives, experience issues related to marriage, separation, divorce, ADHD, anxiety, depression, suicidal ideation, addiction, chronic illness, autism, aging and loss of loved ones, strokes, heart attacks, cancer, dementia and more. And the strain of those is compounded by the 24/7 news cycle, in addition to the pandemic.” (Photo, left to right: Beth Rowell, Vicky Childres, Leigh Kruszenski, Beth Johnson)
She adds, “There was no oasis where people of all ages could go to take a breath, to catch up, to reset from the many difficulties life brings. Managing the stress and anxiety of today’s world, and the toll it can take on your body and mind, is a daunting task. Life can be hard. We wanted to create a space that made it a little easier.” And that was the birth of the ReSet Lounge, a 3,600 square foot health and wellness studio at 530 East Washington St., Chagrin Falls.
In addition to their shared philosophy about healthy living and a strong family life, each founder brought special skills and experience to the new enterprise: Vicky Childres was a fashion director for Saks Fifth Avenue, owned a home décor shop, and is currently CEO of CGL Real Estate Holdings (and lead singer of Soulshine.) Beth Johnson is a long-time business executive and technology consultant. Leigh Kruszenski is a Certified Functional Medicine Health Coach, passionate about empowering people to be stewards of their own health. And Beth Rowell is a Certified Personal Trainer with 20+ years of fitness industry experience.
Co-founder Kruszenski says “ReSet’s services target inflammation, pain, toxins, stress and anxiety while promoting circulation, strength, happiness and sounder sleep.” These unique services include cryotherapy, infrared saunas, salt therapy, massage and compression chairs, whole body vibration, zero gravity positioning, vitamin IV infusions, supplements, and NuCalmÒ neuroscience therapy. ReSet’s trainers and coaches offer personal training, health coaching and advice on vitamin supplements to boost one’s immune function.
One of Reset Lounge’s most popular offerings is the award-winning, FDA-approved NuCalmÒ therapy, clinically proven to combat stress and improve sleep patterns, to ‘reset’ important systems in your body. Without drugs or side-effects, NuCalm calms the body by counteracting adrenaline, stimulating microcurrents, calming the pace of brain waves, and blocking visual stimuli to encourage relaxation. Research shows that a 20-minute session may provide the equivalent of up to two hours of deep, restorative sleep.
The NuCalmÒ system involves a biosignal processing disc placed on the wrist, noise-cancelling headphones, the NuCalm App providing neuroacoustic software, and an eye mask, while resting in a zero-gravity recliner.
One 16-year-old NuCalmÒ user said, “I felt like I was back in the womb -- so safe.” The mother of an 8 year old with ADD cried while watching her daughter’s session, and exclaimed, “I never saw her so still and relaxed before.” A 21-year-old who struggled with insomnia since age 11 tried several traditional cures until she found NuCalmÒ at ReSet: “My body and mind were so relaxed after my first session yet I felt completely energized - I decided I needed to use NuCalm daily. I bought my own unit and now my overall sleep quality is much more restful, and the anxiety I had for years is finally relieved.”
Adding NuCalm to the vitamin IV infusions allows a client to ‘stack’ their recovery; as NuCalm puts the body in a parasympathetic recovery state and allows for a better absorption rate while stress is reduced.
When asked about the ReSet Lounge concept, Johnson said she, “wanted to make services available that I wish I had when my children were younger. I realized that in my middle-aged life, I was the perfect client.” Co-founder Childres said, “I wanted to create a space where one could unplug and escape the noise of our 24/7 news cycle world -- a space where the mind and the body could take a deep exhale, a space where one could solely focus on a mind and body reset.”
Kruszenski adds, “Having gone through my own health journey and realizing that lifestyle changes can have such a profound impact on overall wellness, I wanted to create a space with resources and services to help people find the tools to make them feel better.”
And co-founder Beth Rowell said, “After going through profound struggles with one of my children, and knowing how a place like ReSet would have been a refuge for both of us during that difficult time, I knew I wanted to be part of creating a place where people could come to recover physically and mentally from the chaos of life… There are many benefits to meditation, but it can be challenging. NuCalmÒ does all the heavy lifting for you and coaxes your body and mind to a deep, restorative state.”
Rowell continued, “Once you experience NuCalmÒ, you’re a convert. Clients travel 35 miles or more to experience our services. Some come from as far as Akron and Youngstown. Another reason for our success: We offer a specialized Midwest combo of wellness services under one roof.”
The patented NuCalmÒ technology has won awards at the Consumer Electronics Show, was featured on NBC’s TodayShow, and has been used for years by professional athletes and elite military operators to achieve accelerated recovery without drugs.
Sessions at the ReSet Lounge range from 20 – 60 minutes for all services and can be reserved online. Prices range from $20 to $60 depending on the service and session length. For more info or to book an appointment, download the ReSet Lounge App or contact : 440-600-2659 / info@resetlounge.com - By Stan Hurwitz / stanhurwitz@gmail.com
Olive Fertility Centre Joins With The Fertility Partners Inc
Significant Platform Extension for Healthcare New Venture
TORONTO, Aug. 5, 2020 /CNW/ - The Fertility Partners ("TFP") announced today it has joined with Vancouver-based Olive Fertility Centre, significantly expanding the foundation for a Canada-wide network of fertility clinics.
The Fertility Partners works with world class fertility clinics, providing access to shared medical, strategic and operational best practices, promoting research and development activities and offering extensive back-office support. Its goal is to foster global best clinical outcomes, an international reputation for excellence, and exceptional patient and employee experiences. The TFP partner model empowers physicians and their teams to focus on doing what they do best- provide the highest quality fertility medicine and services.
Says TFP's Founder, CEO & Executive Chairman Dr. Andrew Meikle, "we are very excited to partner with Olive Fertility Centre, voted Best Fertility Clinic in Vancouver for each of the past four years. It is recognized across Canada for its quality of patient care and delivers some of the highest pregnancy rates in the country. Olive also won the prestigious Globe & Mail 2020 Employee Recommended Workplace Award, and this commitment to helping its people thrive will enrich and provide a model for us all." TFP Chief Medical Officer Dr. Al Yuzpe says, "bringing The Olive Fertility Centre into our platform will allow our member clinics to deliver enhanced patient care via shared clinical and scientific innovations that will further improve our patients' experience and treatment outcomes."
The Fertility Partners prides itself on fostering a culture that is patient focused, collaborative, inclusive and transparent. Olive Fertility Centre will retain a high level of independence and complete clinical autonomy, while benefitting from the range of support services its new parent company can offer.
Dr. Jason Hitkari, Medical Director of Olive Fertility Centre states, "we are absolutely thrilled to be partnering with The Fertility Partners. The idea of working collaboratively with other fertility clinics within the partnership to optimize clinical outcomes, pursue evidence-based research, and move innovation forward is very exciting to all of us here at Olive Fertility Centre. Our vision of providing exceptional patient-centred care along with exceptionally good patient outcomes aligns perfectly with what The Fertility Partners is trying to achieve for patients across the country."
About The Fertility Partners: The Fertility Partners is a new venture creating a network of respected fertility clinics across North America. The company aims to be a world class business partner of choice for leading IVF and prenatal practitioners with the goal of achieving global best clinical outcomes, operational excellence and exceptional patient experiences. TFP provides partner clinics with back office support and a collaborative, synergistic medical-scientific, professional and business environment. For more information, please visit www.thefertilitypartners.com.
About Olive Fertility Centre: With offices in Vancouver, Richmond and Surrey BC, Olive Fertility Centre offers a state-of-the-art laboratory facility, personalized care, and advanced fertility treatments such as IVF, Preimplantation Genetic Testing (PGT-A) and egg freezing. Olive is committed to providing fertility treatments that are patient centred, safe, effective, efficient, timely, and equitable. The Centre aspires to provide the highest quality services to patients, continually improve standards of care, and be recognized as the best fertility clinic in Canada. For more information, please visit www.olivefertility.com.
SOURCE The Fertility Partners
Samsung Unveils Five New Galaxy Devices To Empower Your Work and Play
Galaxy Note20 5G and Galaxy Note20 Ultra 5G are productivity powerhouses, seamlessly connecting with the Galaxy ecosystem to help you live every moment to the fullest.
MISSISSAUGA, ON, Aug. 5, 2020 /CNW/ - Today, Samsung Electronics Canada participated in the first-ever Galaxy Unpacked virtual event to introduce a new suite of powerful devices, livestreamed from Korea. Five devices were revealed during the event, that seamlessly integrate to empower consumers navigating a rapidly changing world: Galaxy Note20 5G and Galaxy Note20 Ultra 5G, the most powerful Note line yet; Galaxy Tab S7 and Galaxy Tab S7+, versatile tablets for productivity and creativity; Galaxy Watch3, a premium smartwatch packed with advanced fitness features; Galaxy Buds Live, stylish and ergonomic earbuds with amazing sound quality; and Galaxy Z Fold2, the next generation foldable smartphone with enhanced refinements1.
"Never before have we relied on technology like we are today. It's how we are staying connected as we navigate the extraordinary challenges faced around the world," said Dr. TM Roh, President and Head of Mobile Communications Business, Samsung Electronics. "Technology must make life easier, not more complex. That's why we have introduced five new power devices. Alone, these devices are powerful tools to help you maximize work and play. Together, as part of the Galaxy ecosystem, they work seamlessly so you can spend your time focused on what matters most."
Galaxy Note20 5G and Note20 Ultra 5G, the Most Powerful Note Series Yet The Galaxy Note20 Series 5G smartphones are productivity powerhouses that work like a computer and let you game like a pro. The series features two innovative devices: Galaxy Note20 Ultra 5G, designed for Note fans who demand the ultimate in performance and productivity, and Galaxy Note20 5G, for broader Note users looking to maximize their time for work and play. Both are built for efficiency, so you can focus on staying connected with the people you love.
Power to Work Today, we need devices that are as flexible as we are, so we can work, play and connect how we want. Take your productivity to the next level with the Galaxy Note20 5G and Note20 Ultra 5G. The latest Galaxy Note series from Samsung helps transform the way you work—empowering you to do more, wherever life takes you. Now, on the Galaxy Note20 5G and Note20 Ultra 5G, the new S Pen and Samsung Notes features provide an even more powerful pen to paper experience2, and these features extend to the Galaxy Tab S7 and Tab S7+ for flexibility and convenience. Plus, a deeper relationship with long-standing Samsung partner, Microsoft, makes the Galaxy Note20 Series 5G and your Windows PC work together seamlessly.
An Advanced S Pen: A favourite among Note loyalists and multitaskers, the enhanced S Pen of the Galaxy Note20 Series 5G offers a superb writing experience so you can capture your ideas whenever inspiration strikes. Galaxy Note20 Series 5G has more lifelike precision than ever to give you true pen-to-paper accuracy and responsiveness3. With the five new Anywhere actions on the S Pen, touchless navigation of your device – like returning to the home screen or taking a screenshot – is as simple as a flick of the wrist.
Flexible and Intelligent Samsung Notes Experience: We need tools designed to let us work anytime, on any device. To help you capture, edit and share your ideas across your compatible phone, tablet or Windows 10 PC, Samsung Notes features auto-save and syncing capabilities, so you can pick up right where you left off as you move from device to device. Samsung Notes easily straightens quick handwritten thoughts into legible penmanship. Giving feedback on-the-go is also easy now that you can annotate and highlight PDFs in the Samsung Notes app. Record audio as you jot down ideas, and just tap a word in your notes to go to that moment in the recording. Keep it all organized with new, intuitive folder management that makes everything easier to find.
Work Smarter Across Devices: The Microsoft Your Phone app with Link to Windows4 integration now enables you to easily access your mobile apps directly from your Windows 10 PC without disrupting your flow. It's simple and convenient to send messages, manage notifications, sync photos, and make and receive calls all from your Windows 10 PC. Add your favourite mobile apps to your Taskbar or Start menu so you don't have to search your phone for favourite social media apps and Gallery. Later this year, you will have the ability to run multiple apps side by side on your Windows 10 PC. You can align your productivity ecosystems across your compatible devices by syncing Samsung Notes to Microsoft OneNote and Outlook, or sync your Reminders with Microsoft Outlook, To Do and Teams5 so your files are at your fingertips, no matter where your work takes you.
Power to Play Samsung is also bringing its Microsoft partnership to the entertainment side of Galaxy Note20 Series 5G, taking mobile play to the next level. Fully immerse yourself in the most powerful mobile gaming experience Samsung has ever engineered into a smartphone, so you can game like a pro from your couch, backyard, or around the house. The Galaxy Note20 5G and Note20 Ultra 5G provide you with the power to be a filmmaker in the palm of your hand without the need for extra equipment.
Your favourite Xbox games on Galaxy Note20 Series 5G: Beginning September 15, 2020, play over 100 Xbox games on your phone or tablet, directly from the cloud (beta) with Xbox Game Pass Ultimate6, including hits like Minecraft Dungeons and Gears 5. The Galaxy Note20 Series 5G gaming experience is further enhanced with its AI game booster and Bluetooth audio response optimization, and 240Hz touch latency on the Galaxy Note20 Ultra 5G. With hyper-fast 5G7 and Wi-Fi 68, get optimized gaming latency in every level and battle. A large and immersive display provides a smooth gaming experience thanks to the fastest Note processor yet9. Galaxy Note20 Series 5G is a pro-gaming set-up that fits in your pocket.
Cinematic Filmmaking in the Palm of Your Hand: With 21:9 aspect ratio and 24fps recording, the 8K camera on the Galaxy Note20 Series 5G now gives you ultra-high resolution and a professional quality video experience. Use powerful Pro Video mode with pro-grade focus, audio, exposure, lighting, zoom speed control, and 120fps shooting at FHD options for cinematic-style videos. Pro lenses and advanced Space Zoom10 allow you to photograph scenes in gorgeous detail. You can also control audio sources on the Galaxy Note20 Series 5G, adjusting and selecting between onboard mics or external sources, so the sound you want comes through clearly. Paired with Galaxy Buds Live, for example, you can record crystal-clear audio even with some noise in the background11.
Master Multitasking with Advanced Samsung DeX: For the first time with Samsung DeX12, wirelessly connect your Galaxy Note20 5G or Note20 Ultra 5G to a compatible Smart TV when you need a bigger screen. Manage two screens simultaneously, so you can text with your friends while watching a video on a compatible Smart TV.
Galaxy Legacy of Power and Performance The Galaxy Note has cemented its status as a power phone. The Galaxy Note20 Series 5G continues that legacy as the most powerful Note series yet13 to give you the things you know, love, and expect from Galaxy.
Galaxy Note20 Series 5G is built with the fastest processor of all our Galaxy smartphones. It features cutting-edge technology and a superb mobile experiences, without sacrificing the iconic design. Both Galaxy Note20 5G and Note20 Ultra 5G introduce new Mystic colours – soft neutral tones with a brand new, textured haze effect.
For the first time in the Note series, the Galaxy Note20 Ultra 5G offers the vivid and bright Dynamic AMOLED 2X display and 120Hz refresh rate14. These features combine to deliver buttery smooth visuals on our best Note display yet, which automatically adjusts to the content you are viewing to extend your battery life. Sporting an all-day intelligent battery15and Super Fast Charging capabilities, get hours of power from minutes of charge16 so you worry less about running out of power.
Samsung 5G leadership delivers next-level power for everything you love to do thanks to hyper-fast 5G17. Galaxy Note20 Series 5G automatically searches and recommends high speed networks and can access Wi-Fi 618 networks with optimized latency for various streaming services. You can be confident your Galaxy Note20 Series 5G hardware and software is better protected end-to-end thanks to the Samsung Knox mobile security platform.
For the first time on a Note device, Ultra-Wideband (UWB) technology delivers an intuitive experience that makes sharing photos and videos with loved ones simple and quick. This advanced directional and spatial awareness technology allows you to simply point your Galaxy Note20 Ultra 5G to another UWB-enabled Galaxy device19, and the Nearby Share feature will automatically identify the people you're facing at the top of your sharing panel.
Unlock New Experiences with the Connected Galaxy Ecosystem Samsung Galaxy products and services are designed to work together effortlessly, helping elevate not only your work and play, but the things that are important to you. Take your Galaxy Note20 Series 5G to the next level by pairing it with other new additions to the Samsung Galaxy: Galaxy Tab S7 and Tab S7+, Galaxy Watch3, and Galaxy Buds Live. With these cutting-edge complements to the Note experience, you can enjoy a seamless ecosystem that helps to you work smarter, play longer, focus on wellness, and communicate with your loved ones.
Galaxy Tab S7 and Tab S7+, Versatile Tablets for Productivity and Creativity Galaxy Tab S7 and Tab S7+ are two versatile tablets that combine the power of a PC and the mobility of a tablet to help users get creative and stay productive. With the latest Galaxy Tab S processor20 and expandable memory up to 512GB21 , both tablets come with a 120Hz refresh rate and have an 11-inch and 12.4-inch display, respectively22.
The Galaxy Tab S7 and Tab S7+ come with a refined S Pen23 and Samsung Notes. Plus, transform your tablet with an optional, redesigned keyboard attachment24 to provide a PC-like experience — helping you get more done in less time. The S Pen is also your ideal creative companion for using excellent drawing and note taking apps such as Clip Studio Paint, Canva and Noteshelf25.
Galaxy Watch3 Galaxy Watch3 is the next-generation companion for managing your routines and smashing your fitness goals. Crafted with premium materials including stainless steel and genuine leather, and featuring a slimmed-down26 version of the popular rotating bezel, Galaxy Watch3 features the craftsmanship of a luxury timepiece while still being comfortable enough to wear around the clock.
This smartwatch isn't just appealing to the eye—it can help center your wellness experience27, sporting the most expansive wellness suite from Samsung yet. Paired with advanced sensor technology, Galaxy Watch3 offers total lifestyle management with an integrated heart rate sensor so you can make informed decisions about your fitness and wellness, and visibly track your improvement28. If you take a hard fall outdoors or in your home, the Fall Detection29 feature enables you to send a SOS message to emergency contacts for added peace of mind. For those who want to stay fit while being at home, Samsung Health provides more than 120 different home training programs so you can track your workout progress on your watch.
Galaxy Buds Live Meet the newest shape of our wireless earbuds – Galaxy Buds Live. With a truly iconic design and comfortable fit, they make a bold fashion statement that projects your unique style. Combining AKG's sound expertise with a 12mm speaker and bass duct that is our biggest ever speaker on Galaxy Buds yet, audio sounds deep and rich so you can enjoy music the way the artist intended. Galaxy Buds Live come with three microphones plus the Voice Pickup Unit that senses when your jaw is moving, and converts this data into voice signals to deliver enhanced sound quality. So you can feel like you're in the boardroom with your colleagues, even when you're working from home. These earbuds also feature Active Noise Cancellation30, pairing both live and spacious sound quality with the ability to tune in (or out) of the world around you.
Reshape What's Possible with Galaxy Z Fold2 Samsung continues to pioneer this novel category of mobile devices by introducing the next generation of foldables— Galaxy Z Fold2. After releasing two foldable devices and listening to user feedback on the most requested upgrades and new features, Samsung unveils the Galaxy Z Fold2 with meaningful innovations that offer users an enhanced refinement of the foldable experience31. Galaxy Z Fold2 combines the portability and flexibility of a smartphone with the power and screen size of a tablet for powerful productivity. Whether folded or unfolded, you can enjoy a luxury mobile experience with the premium design of Galaxy Z Fold2. The Galaxy Z Fold2 comes packed with two edge-to-edge, nearly bezel-less Infinity-O Displays. The Cover Screen is 6.2-inches32 and the large Main Screen is 7.6-inches33, making them both larger than the previous Galaxy Fold. With its sleek design and refined engineering, Galaxy Z Fold2 comes in two equally stunning colours: Mystic Black and Mystic Bronze. Samsung is building on its longstanding partnerships with Google and Microsoft to design a superb foldable experience. With Galaxy Z Fold2, Samsung will continue to inspire new possibilities for the foldable category.
Pre-Order and Early Purchase Offers Samsung is excited to be bringing our latest innovations to Canadian consumers in 2020. Canadians who pre-order the Galaxy Note20 Series 5G on Samsung.com/ca between August 5 and August 20, 2020 and complete their purchase will receive their choice of: (i) a Xbox Game Pass Bundle; or (ii) Galaxy Buds Live with purchase of Galaxy Note20 Ultra 5G, or Galaxy Buds+ with purchase of Galaxy Note20 5G34.
Canadians who purchase either Galaxy Buds Live35 or Galaxy Watch336 on Samsung.com/ca between August 5 and September 4, 2020 will receive a Wireless Charger Pad or Wireless Duo Pad, respectively.
At Samsung Experience Stores and all other partner locations, be among the first 15,000 Canadian customers to own the Galaxy Note20 Series 5G between August 5 and September 4, 2020 to receive an e-voucher redeemable online at Samsung.com/ca for your choice of: (i) a Xbox Game Pass Bundle; or (ii) Galaxy Buds Live with purchase of Galaxy Note20 Ultra 5G, or Galaxy Buds+ with purchase of Galaxy Note20 5G37.
At Samsung Experience Stores and all other partner locations, be among the first 3,300 Canadian customers to purchase Galaxy Buds Live38 between August 5 and September 4, 2020 to receive an e-voucher redeemable online at Samsung.com/ca for a Wireless Charger Pad.
At Samsung Experience Stores or at all other partner locations, be among the first 1,700 Canadian customers to purchase Galaxy Watch339 between August 5 and September 4, 2020 to receive an e-voucher redeemable online at Samsung.com/cafor a Wireless Duo Pad.
For customers looking to experience the latest Galaxy innovations in-store, please join us at one of our Samsung Experience Store locations across Canada, including the new Montreal Eaton Centre location opening today, August 5, 2020. Stores are located at:
CF Sherway Gardens
CF Toronto Eaton Centre
Metropolis at Metrotown
Montreal Eaton Centre
West Edmonton Mall
Yorkdale Shopping Centre
Availability
Galaxy Note20 5G and Galaxy Note20 Ultra 5G: Available for pre-order now at Samsung Experience Stores or through Samsung.com/ca, as well as across major Canadian carriers and retail partners, and available for purchase at retail as of August 21, 2020.
Galaxy Note20 5G will be available in Mystic Bronze, Mystic Grey and Mystic Green, with pricing starting at $1,399.99 (regular price).
Galaxy Note20 Ultra 5G will be available in Mystic Bronze and Mystic Black, starting at $1,819.99 (regular price) for the 128GB model and $2,029.99 (regular price) for the 512GB model (available in Mystic Black only).
Galaxy Tab S7 and Galaxy Tab S7+: Available in two variants - 128GB (Mystic Black, Mystic Silver, Mystic Bronze) and 256GB (Mystic Black) online at Samsung.com/ca and in-store at Samsung Experience Stores as well as major retailers across Canada starting on September 18, 2020. Galaxy Tab S7 pricing starts at $919.99 (regular price) for the 128GB model and $1,029.99 (regular price) for the 256GB model (Mystic Black only). Galaxy Tab S7+ pricing starts at $1,189.99 (regular price) for the 128GB model, and $1,299.99 (regular price) for the 256GB model (Mystic Black only).
Galaxy Watch3: Available in 45mm (Mystic Black, Mystic Silver) and 41mm (Mystic Bronze, Mystic Silver) online at Samsung.com/ca and in-store at Samsung Experience Stores as well as major retailers across Canada starting on August 5, 2020 for $549.99 (regular price) for the 41mm model and $599.99 (regular price) for the 45mm model.
Galaxy Buds Live: Available online at Samsung.com/ca starting August 5, 2020 in Mystic Bronze, Mystic White and Mystic Black for $249.99 (regular price) and in-stores at Samsung Experience Stores and major retailers across Canada starting August 21, 2020.
Galaxy Z Fold2: Will be available in Canada later this year – pricing and availability details to come.
*Infinity-O Display: a near bezel-less, full-frontal screen.*Measured diagonally, Galaxy Note20's screen size is 6.7" in the full rectangle and 6.6" with accounting for the rounded corners and Galaxy Note20 Ultra's screen size is 6.9" in the full rectangle and 6.8" with accounting for the rounded corners; actual viewable area is less due to the rounded corners and camera hole.*120Hz display only available on Galaxy Note20 Ultra.
Dimensions & Weight
[Device] 164.8 x 77.2 x 8.1mm, 208g
[Device] 161.6 x 75.2 x 8.3mm, 192g
[S Pen] 5.8 × 4.35 × 105.08mm, 3.04g
S Pen
Bluetooth enabled, Lithium Titanate Battery: Up to 24 hours of battery standby timePressure levels: 4096, Pen tip diameter: 0.7 mm, IP68
*S Pen's operable distance extends approximately 10 meters from the device in open space. Control range may vary depending on surroundings and other factors.*Using S Pen as a stylus does not require battery power. Actual battery life may vary depending on usage patterns and other factors.*IP68 rating is based on test conditions for submersion in up to 1.5 meters of freshwater for up to 30 minutes. Rinse residue/dry if wet.
*12MP Ultra Wide Camera. Pixel size: 1.4μm. FOV: 120˚. F.No (aperture): F2.2 *12MP Wide-angle Camera. Super Speed Dual Pixel AF, OIS. Pixel size: 1.8μm . FOV: 79˚. F.No (aperture): F1.8. 1/1.76" image sensor size *64MP Telephoto Camera. Pixel size: 0.8μm. FOV: 76˚. F.No (aperture): F2.0 Space Zoom . 3x Hybrid Optic Zoom . Up to 30x Super Resolution ZoomOIS (Optical Image Stabilization)Tracking AF
*Galaxy Note20's Hybrid Optic Zoom combines high-resolution image sensor and lens.*Super Resolution Zoom includes digital zoom, which may cause some image deterioration.
12GB RAM (LPDDR5) with 512GB internal storage12GB RAM (LPDDR5) with 128GB internal storage
8GB RAM (LPDDR5) with 128GB internal storage
* Actual storage available may vary depending on pre-installed software.
ExpandableMemory & SIM Card
Single SIM model: one Nano SIM and one MicroSD slot (up to 1TB)
*Expandable memory only available on Galaxy Note20 Ultra. MicroSD card sold separately.
Battery
4,500mAh (typical)
4,300mAh (typical)
*Typical value tested under third-party laboratory condition. Typical value is the estimated average value considering the deviation in battery capacity among the battery samples tested under IEC 61960 standard. Rated (minimum) capacity is 4170mAh for Galaxy Note20 and 4370mAh for Galaxy Note20 Ultra. Actual battery life may vary depending on network environment, usage patterns and other factors.
Charging
Improved wireless charging speeds with Fast Wireless Charging 2.0USB PD 3.0 (PPS) certified Fast Charging for wired charging (AFC and QC2.0 compatible)*WPC certified Wireless charging*Wireless PowerShare
Fast Wireless Charging 2.0 currently available with Wireless Charger Stand, Wireless Charger Duo Pad, and other devices that support 10W or more wireless charging. Sold separately. Actual charging speed may vary depending on the actual usage, charging conditions, and other factors. Wireless charger requires power connection. Recommend using in-box charging cable and/or travel adapter for use of third party items may cause damage to the Wireless Charger Stand and Wireless Charger Duo Pad or a decrease in charging speed. *Wireless PowerShare is limited to Samsung or other brand smartphones with Qi wireless charging, such as Galaxy Z Fold2, Galaxy Note20, Galaxy Note20 Ultra, Galaxy S20, S20+, S20 Ultra, Z Flip, Note10, Note10+, S10e, S10, S10+, Fold, S9, S9+, S8, S8+, S8 Active, S7, S7 edge, S7 Active, S6, S6 edge, S6 Active, S6 edge+, Note9, Note8, Note FE, Note5, and wearables such as Galaxy Buds Live, Galaxy Watch3, Galaxy Watch Active2, Galaxy Watch Active, Gear Sport, Gear S3, Galaxy Watch, and Galaxy Buds. If battery power is lower than 30% Wireless PowerShare may not function. May not work with certain accessories, covers, other brand devices, or some Samsung wearables. May affect call reception or data services, depending on your network environment.
OS
Android 10
Network
[5G] 5G Non-Standalone (NSA), Standalone (SA), Sub6[LTE] Enhanced 4x4 MIMO, Up to 7CA, LTE Cat.20, Up to 2.0Gbps Download / Up to 200Mbps Upload[Wi-Fi] Wi-Fi 802.11 a/b/g/n/ac/ax 2.4G+5GHz, HE80, MIMO, 1024-QAM, Up to 1.2Gbps Download / Up to 1.2Gbps Upload[Bluetooth] Bluetooth® v 5.0, USB type-C, NFC, Location (GPS, Galileo, Glonass, BeiDou)[Ultra Wide Band]
*Actual speed may vary depending on market, carrier, and user environment.*Requires optimal 5G connection. Actual speed may vary depending on market, carrier, and user environment.*Galileo and BeiDou coverage may be limited. BeiDou may not be available for certain markets.*Ultra Wide Band supported on Galaxy Note20 Ultra.
Lock type: pattern, PIN, passwordBiometric lock type: Fingerprint, Face recognition
Audio
[Stereo Speakers by AKG]Surround sound with Dolby Atmos technology (Dolby Digital, Dolby Digital Plus included.) [Ultra high quality audio playback]UHQ 32-bit &DSD64/128 supportPCM: Up to 32 bits, DSD: DSD64/128*DSD64 and DSD128 playback can be limited depending on the file format. [Audio playback format]MP3, M4A, 3GA, AAC, OGG, OGA, WAV, WMA, AMR, AWB, FLAC, MID, MIDI, XMF, MXMF, IMY, RTTTL, RTX, OTA, APE, DSF, DFF [Bluetooth]Dual Audio: connect two Bluetooth devices to the Galaxy Note20 or Note20 Ultra to play audio through the two devices simultaneously.*The two connected devices may exhibit a slight difference in sound output. Scalable Codec: Enhanced Bluetooth connection under ambient radio frequency interference.*Available only for certain accessories made by Samsung. [Recording]Recording quality is improved with the High AOP Mic that minimizes distortion in noisy environments.*AOP: Acoustic Overload Point
Video
[Video playback format]MP4, M4V, 3GP, 3G2, WMV, ASF, AVI, FLV, MKV, WEBM [TV connection]Wireless: Smart View (screen mirroring 1080p at 30 fps)Wired: supports DisplayPort over USB type-C. Supports video out when connecting via HDMI Adapter. (DisplayPort 4K UHD at 60 fps)
Water Resistance
IP68
*IP68 is based on test conditions for submersion in up to 1.5 meters of freshwater for up to 30 minutes. Rinse residue/dry if wet. Not advised for beach or pool use.
* Specs subject to change without notice. Specs vary by markets/carriers.
* All functionality, features, specifications and other product information provided in this document including, but not limited to, the benefits, design, pricing, components, performance, availability, and capabilities of the product are subject to change without notice.
About Samsung Electronics Canada Inc. Samsung Electronics Canada inspires Canadians to reach their full potential through a transformative ecosystem of products and services that deliver innovation and distinct design to every aspect of their connected lives. The company is redefining the worlds of TVs, smartphones, virtual reality and wearable devices, tablets and digital appliances. In 2020, Samsung was ranked as one of Canada's "Most Reputable Companies" in Leger's Corporate Reputation Study. Dedicated to helping make a difference in the lives of Canadians, Samsung's award-winning corporate giving initiatives support public education and health-related issues in communities across the country. To discover more, please visit www.samsung.com/ca.
1 Compared to Galaxy Fold
2 Compared to Galaxy Note10
3 Galaxy Note20 5G has 40% latency improvement over Note10;Galaxy Note20 Ultra has 80% latency improvement (down to 9ms) over Note10.
4 Link to Windows requires the Your Phone app (free download), a Microsoft account and Windows 10. Some mobile apps may have security features that prevent the mobile app from being viewed on PC.
5 Service will be available starting later this year. Need to be signed into the same Microsoft account. Microsoft Outlook sync for web version only
6 Service available in Canada later this year. Controller may be needed to play some games from Xbox Game Pass Ultimate. Controller sold separately. Paid subscription to Xbox Game Pass Ultimate required. Game streaming (beta) available from September 15, 2020; requires Xbox Game Pass Ultimate, sufficient network speed, and supported controller (each sold separately). Streaming limits apply. Catalog varies over time and by market. Actual speed may vary depending on market, carrier, and user environment.
7 Requires optimal 5G network connection, available in select markets. Check with your carrier for availability and details. Download and streaming speeds may vary based on content provider, server connection and other factors.
8 Faster than previous Wi-Fi protocols. Only available where Wi-Fi 6 is supported. Availability of Wi-Fi 6 support may vary depending on country or region.
9 Compared to Galaxy Note10.
10 Space Zoom includes digital zoom, which may cause some image deterioration.
11 Compatible with Bluetooth or USB-C accessories, sold separately.
12 Samsung DeX wireless connection requires smart TV with Miracast support; both devices must be on same Wi-Fi network. Samsung DeX provides optimized experience with Samsung smart TV launched after 2019
13 Compared to Galaxy Note10.
14 Default screen refresh rate is 60Hz. Requires screen setting at 120Hz screen refresh rate.
15 Based on average battery life under typical usage conditions. Average expected performance based on typical use. Actual battery life depends on factors such as network, features selected, frequency of calls and voice, data, and other application usage patterns. Results may vary.
16 When using the included charger and cable.
17 Requires optimal 5G network connection, available in select markets. Check with your carrier for availability and details. Download and streaming speeds may vary based on content provider, server connection and other factors.
18 Faster than previous Wi-Fi protocols. Only available where Wi-Fi 6 is supported. Availability of Wi-Fi 6 support may vary depending on country or region.
19 Point to Share works between Samsung devices that support UWB.
20 Thirty percent faster compared to Galaxy Tab S6
21 MicroSD sold separately
22 Galaxy Tab S7 11" screen is a LTPS TFT LCD screen. Galaxy Tab S7+ 12.4" screen is a sAMOLEDTM screen. Measured diagonally as a full rectangle without accounting for the rounded corners. Actual viewable area is less due to the rounded corners.
23 Compared to Galaxy Tab S6 S Pen.
24 Keyboard accessory sold separately.
25 Canva and Noteshelf are proloaded in Tab S7｜S7+ as a stub. Clip Studio Paint is preloaded in S7｜S7+ however the preload may not be supported in some regions. Clip Studio Paint is available in the Galaxy Store.
26 14% thinner, 8% smaller and 15% lighter than the original Galaxy Watch3
27 Intended for general wellness and fitness purposes only.
28 Intended for general wellness and fitness purposes only. Heart rate tracking function on the watch can be used as standalone, but data stored in the watch may only be partially displayed after a certain period of time. Smartphone pairing is recommended in order to keep all data stored.
29 This feature is intended for fitness and wellness purposes only and is not intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease.
30 Features including Active Noise Cancellation are enabled through a Bluetooth connection or the Galaxy Wearable app on Android, available through the Galaxy Store or Google Play Store, and the Galaxy Buds app on iOS devices, available through the App Store.
31 As compared to Galaxy Fold.
32 Measured diagonally, the screen size is 6.2" in a full rectangle and 6.2" accounting for the rounded corners. The actual viewable area is smaller due to the rounded corners and camera hole.
33 Measured diagonally, the screen size is 7.6" in a full rectangle and 7.6" accounting for the rounded corners. The actual viewable area is smaller due to the rounded corners and camera hole.
34 Terms and conditions apply. Pre-order a Galaxy Note20 5G or Galaxy Note20 Ultra 5G on www.samsung.com/ca from August 5th – August 20th, 2020 and receive a bonus gift upon completion of your device purchase as shown above (customers' choice). While quantities last. No rain checks. Limit of one bonus per device purchase. Open to Canadian Residents only. For full details, visit www.samsung.com/ca/promotions.
35 Terms and conditions apply. Purchase Galaxy Buds Live from August 5th – September 4th 2020 on samsung.com/ca and receive and receive a bonus Wireless Charger Pad. While quantities last. No rain checks. Limit of one bonus per device purchase. Open to Canadian Residents only. For full details, visit www.samsung.com/ca/promotions.
36 Terms and conditions apply. Purchase a Galaxy Watch3 from August 5th – September 4th 2020 samsung.com/ca and a bonus Wireless DuoPad. While quantities last. No rain checks. Limit of one bonus per device purchase. Open to Canadian Residents only. For full details, visit www.samsung.com/ca/promotions.
37 Terms and conditions apply. Be among the first 15,000 customers to either (i) pre-order from August 5th – August 20th, 2020, or (ii) purchase from August 2st – September 4th, 2020 a Galaxy Note20 5G or a Galaxy Note20 Ultra 5G and receive an E-Voucher upon completion of your purchase (redeemable on Samsung.com/ca Aug18 – Sept 30, 2020 for one of either a Microsoft Game Pass Bundle or Samsung Buds+ (for purchase of Galaxy Note205G) OR one of either a Microsoft Game Pass Bundle or Galaxy Buds Live (for purchase of Galaxy Note20 Ultra 5G). E-Vouchers can be downloaded from the Samsung Members app on your Galaxy Note20 5G or Galaxy Note20 Ultra 5G in the Benefits Section between Aug 18 – Sept 30, 2020. Visit Samsung.com/evoucher for full details.
38 Terms and conditions apply. Purchase Galaxy Buds Live from August 5th – September 4th 2020 and receive an E-Voucher redeemable on samsung.com/ca between August 18th and September 30th 2020 for a bonus Wireless Charger Pad. While quantities last. No rain checks. Limit of one bonus per device purchase. Open to Canadian Residents only. For full details, visit www.samsung.com/ca/promotions.
39 Terms and conditions apply. Purchase a Galaxy Watch3 from August 5th – September 4th 2020 and receive an E-Voucher redeemable on samsung.com.ca between August 18th and September 30th, 2020 for a bonus Wireless DuoPad. While quantities last. No rain checks. Limit of one bonus per device purchase. Open to Canadian Residents only. For full details, visit www.samsung.com/ca/promotions.
SOURCE Samsung Electronics Canada Inc.
WORK PRODUCTIVITY vsSOCIETAL ANXIETY & STRESS
Neuroscience Expert Shares Tips to Reduce Stress, Improve Mental Clarity & Beat Distraction So You Can Focus at Work-Solutions & Advice for the American Workforce-Whether you work at home or in an office, it’s easy to get distracted. Our phones, computers, TVs, family, friends, and coworkers have always been barriers to productivity...And in the age of COVID-19, it's even more difficult to concentrate. According to a recent survey, 59% of people said they now can’t use shared spaces in their workplace without fear. Parents working at home now have the added distraction of supervising and teaching their kids 24/7 and even those without children are having trouble focusing; 64% of respondents shared they aren’t as productive because of pandemic-related stress and anxiety. According to Neuroscience expert Dr. Patrick Porter, mental clarity is crucial for productivity. "Increased stress and anxiety surrounding COVID-19 has understandably caused work productivity to plummet because your emotional state is directly connected to your ability to focus..."...says Dr. Porter, who has devoted his career to researching the brain and mental wellness. According to Dr. Porter, stress, anxiety, and fear elevate cortisol levels in the brain which interferes with memory making it impossible to concentrate on your work. Not only is this bad for employees who are stressed out and scrambling to make ends meet with growing to do lists - it is also bad for entire corporations and businesses as the decrease in productivity significantly impacts a company's bottom line. "Luckily, there are strategies you can do to improve mental clarity and reduce stress so you can beat distraction and focus..."...says Dr. Porter. One productivity-boosting strategy he recommends is to take a "time-out" every 75 to 90 minutes. While it may sound counterintuitive, many studies have shown a link between taking breaks and increased productivity. Stepping away from work for 10-15 minutes resets your brain, allows your mind to relax, and gets you in a clear headspace. Dr. Porter is also an advocate of restorative activities like exercising and meditating - both of which increase your ability to focus on tasks and remember information. Dr. Porter is sharing productivity-boosting tips for the American workforce. He has brain-based strategies and actionable advice people can use to reduce stress, beat distraction, and increase mental clarity, and focus. TALKING POINTS (FOR INTERVIEWS & ARTICLES):How to Focus in the Office Amid COVID Anxiety & StressTips to Improve Mental Clarity & Focus While Working at Home (& Distracted by Kids)Strategies to Survive Working From Home With Children How to Reframe Anxiety & Channel It Into Motivation & ProductivityFascinating Science Behind Stress, The Brain, & Productivity7 Ways to Stay Productive When You're StressedHow Sleep Impacts Productivity at WorkProductivity & The Pandemic: The Mental Health Impact of COVID-19 on Business & WorkHow Managers and Employers Can Help Their Team Stay Focused ABOUT DR. PATRICK PORTER: Patrick K. Porter, Ph.D., is an award-winning author and speaker who has devoted his career to neuroscience and brainwave entrainment. As the creator of BrainTap®, Dr. Porter has emerged as a leader in the digital health and wellness field. BrainTap’s digital tools and mind development apps use creative visualization and relaxation, biohacking techniques that have made tremendous advances in helping mental, physical, and emotional health issues. BrainTap has been praised for helping people relieve symptoms associated with stress, insomnia, pain, and much more. FOR MORE INFORMATION, VISIT:https://braintap.com
Research to help elderly manage medicines safely could help cut hospital admissionsNew £156,000 two-year study led by University of Bradford academic
04 August 2020 Helping frail elderly people manage multiple medicines safely is the focus of a new research project led by Dr Beth Fylan, Senior Lecturer in Patient Safety in the Faculty of Life Sciences at the University of Bradford.The potential impact is considerable: nearly 12 million people in the UK are over 65 and of those, around half suffer from more than one chronic condition, usually requiring them to take multiple medicines over a long period of time. Older people are also more likely to experience avoidable adverse drug events.The £156,000 project will run for two years and is funded by the National Institute for Health Research (NIHR). It is being run through the NIHR Patient Safety Translational Research Centre and the Wolfson Centre for Applied Health Research, which are collaborations between the University of Bradford, Bradford Teaching Hospitals NHS Trust and the University of Leeds.Dr Fylan explains: “Frail older people’s medicines regimens are often extremely complicated and it requires significant work to manage them safely. When older people aren’t supported to do this, they may be more likely to be admitted into hospital or suffer a fall from which they can find it hard to recover, leading to a downward spiral. Our aim is to help them manage things better, so they never enter that cycle.”Rather than unpicking the causes of poor medicines management after something has gone wrong, the project aims to take a different approach, using a resilient healthcare framework.This means the team will identify the safe and successful strategies older people and their carers can use to manage their medicines, including how they respond to changes in their own health and anticipate problems such as mistakes in repeat prescriptions. The researchers will then build on these insights to design an intervention with patients and healthcare staff to help others achieve similar success.The project will focus on people over 65 who are taking multiple medicines and are categorised as mildly or moderately ‘frail’. This means they have a range of symptoms, such as hearing loss and tremors, and health conditions, such as heart disease or arthritis, all of which make them more vulnerable.The team – involving academics, clinicians and patients at the University of Bradford, Bradford Teaching Hospitals NHS Trust, the University of Leeds and Doncaster Clinical Commissioning Group – will work with eight GP practices across Yorkshire and Humber. They will interview patients and carers to understand the strategies they use and how the healthcare system supports or hinders these. Extracts from these interviews will be made into a short film that will be shown at workshops with healthcare staff, patients and carers to trigger thoughts, ideas and discussion about the issues raised.Participants in the workshops will help identify the most important ideas to take forward, based on all the evidence presented and develop prototype interventions.“It’s important that solutions are designed jointly by staff, carers and patients as each group has an important perspective on the challenges faced,” said Dr Fylan. “It’s a fascinating process to be part of – you can never predict what might come out of it. It could be as varied as a toolkit for patients to use at home or a ‘buddy scheme’ providing peer support to give patients and carers more confidence to talk to healthcare staff about any problems.”The interventions identified through the workshops will then be tested in focus groups – again comprising healthcare staff, patients and carers – to see how easily they would be accepted by patients and their feasibility. The final outcome should be a system that is ready to be evaluated in a trial, alongside guidance for putting it into practice. Pictures 1) Dr Beth Fylan, Senior Lecturer in Patient Safety in the Faculty of Life Sciences at the University of Bradford, 2) Generic shot of medication. Credit: University of Bradford.
Janssen Announces Health Canada Approval of DARZALEX®* SC, a New Subcutaneous Formulation for the Treatment of Patients with Multiple Myeloma
DARZALEX® SC reduces administration time from hours to minutes and demonstrates consistent efficacy with a reduction in administration-related reactions compared to intravenous DARZALEX® (daratumumab)
TORONTO, Aug. 4, 2020 /CNW/ - The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that Health Canada has approved DARZALEX® SC (daratumumab), a new subcutaneous formulation of daratumumab.1DARZALEX® SC is approved in four regimens across five indications in patients with multiple myeloma, most notably newly diagnosed, transplant-ineligible patients as well as relapsed or refractory patients. As a fixed-dose formulation, DARZALEX®SC can be administered over approximately three to five minutes, significantly less time than intravenous (IV) DARZALEX®, which is administered over hours.2 DARZALEX® SC is the only subcutaneous CD38-directed antibody approved in the treatment of multiple myeloma.
In the Phase 3 COLUMBA study published in The Lancet, DARZALEX® SC demonstrated a consistent overall response rate (ORR) and pharmacokinetics and a similar safety profile compared with IV DARZALEX® in patients with relapsed or refractory multiple myeloma. In addition, there was a nearly two-thirds reduction in systemic administration-related reactions (ARRs) for DARZALEX® SC compared to IV DARZALEX® (13 per cent vs. 34 per cent, respectively).3
"DARZALEX® has become a backbone therapy in the treatment of multiple myeloma, supported by a robust body of evidence in both the frontline and relapsed and refractory settings," says Dr. Darrell White, Hematologist, Queen Elizabeth II Health Sciences Centre, Halifax. "With this new subcutaneous formulation, not only is treatment much more convenient for patients, but it will also play a very important role in reducing wait times and the burden on our busy healthcare system, especially during this time."
The approval is based on data from the Phase 3 COLUMBA and Phase 2 PLEIADES studies.4,5 In the COLUMBA study, the ORR was non-inferior for patients taking DARZALEX® SC as monotherapy compared to those taking IV DARZALEX® as monotherapy (41 per cent vs. 37 per cent, respectively). 6 Additionally, in the Phase 2 PLEIADES study evaluating the efficacy and safety of DARZALEX® SC in combination therapies, objective responses were demonstrated in combination with bortezomib, melphalan and prednisone (D-VMP) in newly diagnosed transplant ineligible patients. In addition, objective responses were demonstrated in combination with lenalidomide and dexamethasone (D-Rd) in relapsed or refractory patients who received one prior line of therapy.7 In a pooled safety population of 490 patients who received DARZALEX® SC as monotherapy or in combination, the ARR rate was 11 per cent.8
DARZALEX® SC is approved in all current IV indications including (1) in combination with bortezomib, melphalan and prednisone in newly diagnosed patients who are ineligible for autologous stem cell transplant, (2) in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant and in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy, (3) in combination with bortezomib and dexamethasone in patients who have received at least one prior therapy, and (4) as monotherapy, in patients who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent.9
Active discussions are ongoing with public insurers to determine how DARZALEX® SC can be made accessible for both relapsed or refractory patients as well as newly diagnosed, transplant ineligible patients.
"This approval exemplifies Janssen's mission and commitment to bringing together passion, science and ingenuity to advance novel solutions for patients," said Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research & Development, LLC.
About the COLUMBA Study The randomised, open-label, multicenter Phase 3 COLUMBA study included 522 patients (median age of 67 years) with multiple myeloma who had received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD), or whose disease was refractory to both a PI and an ImiD. In the arm that received DARZALEX® SC (n=263), patients received a fixed dose of DARZALEX® SC 1,800 milligrams (mg), co-formulated with recombinant human hyaluronidase PH20 (rHuPH20) 2,000 Units per milliliter (U/mL), subcutaneously weekly for Cycles 1 – 2, every two weeks for Cycles 3 – 6 and every four weeks for Cycle 7 and thereafter. In the IV DARZALEX® arm (n=259), patients received DARZALEX® for IV infusion 16 milligrams per kilogram (mg/kg) weekly for Cycles 1 – 2, every two weeks for Cycles 3 – 6 and every four weeks for Cycle 7 and thereafter. Each cycle was 28 days. In the arm that received DARZALEX® SC, it was given in a fixed volume of 15 mL over three to five minutes; the median injection time was five minutes. In the arm that received the IV administration, the median durations of the first, second and subsequent IV DARZALEX® infusions were 7.0, 4.3 and 3.4 hours, respectively. Patients in both arms continued treatment until disease progression or unacceptable toxicity.10,11
About the PLEIADES Study The non-randomised, open-label, parallel assignment Phase 2 PLEIADES study included adults with multiple myeloma, including 67 patients with newly diagnosed multiple myeloma who were treated with 1,800 mg of DARZALEX® SC in combination with bortezomib, melphalan, and prednisone (D-VMP) and 65 patients with relapsed or refractory disease who were treated with 1,800 mg of DARZALEX® SC plus lenalidomide and dexamethasone (D-Rd). The primary endpoint for the D-VMP and D- Rd cohorts was overall response rate.12
About DARZALEX® and DARZALEX® SC DARZALEX® is the first CD38-directed monoclonal antibody (mAb) approved to treat multiple myeloma and in 2020, DARZALEX® SC (daratumumab) follows as the only subcutaneous CD38-directed antibody approved to treat patients with multiple myeloma.13 It binds to CD38, a surface protein highly expressed across multiple myeloma cells.14 DARZALEX® induces tumor cell death through cell lysis via multiple immune-mediated mechanisms of action, including complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP).15 DARZALEX® has also demonstrated immunomodulatory effects such as increasing CD4+ and CD8+ T-cells counts, which may contribute to clinical response.16
In August 2012, Janssen Biotech, Inc. and Genmab A/S entered a worldwide agreement, which granted Janssen an exclusive license to develop, manufacture and commercialize DARZALEX®. Janssen Inc. commercializes DARZALEX® and DARZALEX® SC in Canada. For full Prescribing Information and more information about DARZALEX® and DARZALEX® SC, please visit www.janssen.com/canada.
About Multiple Myeloma Multiple myeloma is an incurable blood cancer that affects a type of white blood cell called plasma cells, which are found in the bone marrow.17 When damaged, these plasma cells rapidly spread and replace normal cells with tumors in the bone marrow. In 2020, it is estimated that 3,400 Canadians will be diagnosed with multiple myeloma and there will be 1,600 deaths associated with the disease.18 While some patients with multiple myeloma have no symptoms in the early stages, patients are diagnosed due to symptoms that can include bone disease or pain, anemia, calcium elevation, and kidney problems.19
About the Janssen Pharmaceutical Companies of Johnson & Johnson At Janssen, we're creating a future where disease is a thing of the past. We're the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension.
Learn more at www.janssen.com/canada. Follow us at @JanssenCanada. Janssen Inc. is a member of the Janssen Pharmaceutical Companies of Johnson & Johnson.
*All trademark rights used under license. **Dr. White was not compensated for any media work. He has been compensated as a consultant.
Cautions Concerning Forward-Looking Statements This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding DARZALEX® SC. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Inc., any of the other Janssen Pharmaceutical Companies and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 29, 2019, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in the company's most recently filed Quarterly Report on Form 10-Q, and the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. None of the Janssen Pharmaceutical Companies nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.
References:
1
[DARZALEX® SC Product Monograph, Janssen Inc., July 29, 2020]
2
[DARZALEX® SC Product Monograph, Janssen Inc., July 29, 2020]
3
Mateos MV, et al. Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial [published online ahead of print March 23, 2020]. Lancet Haematol doi.org/10.1016/S2352-3026(20)30070-3.
4
Mateos M-V et al. Efficacy and Safety of the Randomized, Open-Label, Non-inferiority, Phase 3 Study of Subcutaneous (SC) Versus Intravenous (IV) Daratumumab (DARA) Administration in Patients (pts) With Relapsed or Refractory Multiple Myeloma (RRMM): COLUMBA. 2019 American Society of Clinical Oncology Annual Meeting. June 2019.
5
Janssen Research & Development, LLC. A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 [cited July 5, 2019]. Available at: https://clinicaltrials.gov/ct2/show/NCT03412565. Identifier: NCT03412565.
6
Mateos MV, et al. Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial [published online ahead of print March 23, 2020]. Lancet Haematol doi.org/10.1016/S2352-3026(20)30070-3.
7
Chari A, M. J., McCarthy H, et al Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy: PLEIADES study update. Poster presented at: 61st American Society of Hematology (ASH) Annual Meeting. Orlando, FL.
8
[DARZALEX® SC Product Monograph, Janssen Inc., July 29, 2020]
9
[DARZALEX® SC Product Monograph, Janssen Inc., July 29, 2020]
10
[DARZALEX® SC Product Monograph, Janssen Inc., July 29, 2020]
11
Mateos MV, et al. Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial [published online ahead of print March 23, 2020]. Lancet Haematol doi.org/10.1016/S2352-3026(20)30070-3.
12
Janssen Research & Development, LLC. A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 [cited July 5, 2019]. Available at: https://clinicaltrials.gov/ct2/show/NCT03412565. Identifier: NCT03412565.
13
Janssen Research & Development, LLC. A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 [cited July 5, 2019]. Available at: https://clinicaltrials.gov/ct2/show/NCT03412565. Identifier: NCT03412565.
14
[DARZALEX® SC Product Monograph, Janssen Inc., July 29, 2020]
15
[DARZALEX® SC Product Monograph, Janssen Inc., July 29, 2020]
16
[DARZALEX® SC Product Monograph, Janssen Inc., July 29, 2020]
17
Kumar, SK et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia. 2012 Jan; 26(1):149-57.
Eastern Ontario Regional Laboratory Association (EORLA) and Roche Diagnostics join forces for seroprevalence study for SARS-CoV-2
EORLA to use Elecsys® Anti-SARS-CoV-2 antibody test that helps determine exposition to the virus and development of antibodies
OTTAWA, ON, Aug. 4, 2020 /CNW Telbec/ - Roche Diagnostics, a division of Hoffmann-La Roche Limited, and the Eastern Ontario Regional Laboratory Association (EORLA) are pleased to announce a major collaborative research initiative on SARS-CoV-2 serology. The EORLA research team will conduct a randomized seroprevalence study of 4,400 people in Eastern Ontario to identify how many have been infected with SARS-CoV-2 and for how long those antibodies remain detectable in the body.
"Our objective is to establish an estimate of the number of Eastern Ontario residents who have been exposed to SARS-CoV-2, but may not be aware of their exposure," said Dr. Christopher McCudden, Deputy Chief Medical/Scientific Officer at EORLA and leader of the study. "We will aim to quantify this exposure first among high-risk hospital out-patients. They are mobile, living in the community, but still need to come to hospital for regular blood tests and follow-up."
The study is also intended to learn more about the pattern by which the amount of antibodies rises and falls over time in SARS-CoV-2 patients. By doing so, EORLA researchers hope to determine the longevity of antibody production in patients, critically important to pandemic response and recovery planning, with wide applications and benefits both regionally and nationally. The study will cover the Champlain Region of Ontario, which includes the National Capital Region and communities east of Algonquin park between the Quebec and New York state borders.
"We are proud to partner with the EORLA for this seroprevalence study using Elecsys® Anti-SARS-CoV-2 antibody test, which we are confident will bring reliable results to better manage the COVID-19 health crisis in Ontario," said Michele D'Elia, Medical Director of Roche Diagnostics. "This study will help answer key questions about COVID-19 epidemiology and immunity and is one of our many efforts across the country to help better understand the dynamics of the pandemic in Canada."
Study results will be invaluable to workers in long-term care homes, regional health centres and hospitals, and the community at large. Further, the study could provide a better understanding of the extent of herd immunity.
About antibody testing An antibody test, also called a serology test, is used to determine whether a person might have mounted an immune response against a pathogen or not. In the current situation of the COVID-19 pandemic, antibody tests need to be able to specifically detect antibodies against SARS-CoV-2 with no cross-reactivity to other similar coronaviruses, which could generate a false positive result and thus wrongly indicate potential COVID infection. A false positive result happens when a person receives a positive test result, when they should have received a negative result. False positives are particularly critical when we do not know how many people in a given population have been exposed to the virus.
About EORLA The Eastern Ontario Regional Laboratory Association (EORLA) is a member-owned, non-profit organization encompassing the operation of 18 licensed, acute-care, hospital-based clinical laboratories that service clinical programs across the Champlain Region of Eastern Ontario. A leading, innovative model of integrated laboratory practices in the province, the purpose of EORLA is to deliver patient-focused, consistent, high-quality and cost-effective hospital-based laboratory services to meet the needs of the region's patients. EORLA laboratories provide diagnostic testing to both hospital inpatients and registered outpatients, performing a total of approximately 13 million tests annually. Comprehensive testing in the disciplines of Anatomic Pathology, Biochemistry, Transfusion Medicine, Hematopathology, and Microbiology/Virology is performed. For more information, visit www.eorla.ca.
About Elecsys® Anti-SARS-CoV-2 serology test1 Elecsys® Anti-SARS-CoV-2 is an immunoassay for the in-vitro qualitative detection of antibodies (including IgG) to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in human serum and plasma. Through a blood sample, the test, which is based on an in-solution double-antigen sandwich format, can detect antibodies to the new coronavirus causing COVID-19, which could signal whether a person has already been infected and potentially developed immunity to the virus. Based on the measurement of a total of 10,453 samples, the Elecsys® Anti-SARS-CoV-2 assay has 99.80% specificity and shows no cross-reactivity to the four human coronaviruses causing common cold. This means it can lower the chance of false positives due to the detection of similar antibodies that may be present in an individual, but are specific for coronaviruses other than SARS-CoV-2. Elecsys® Anti-SARS-CoV-2 detected antibodies with 99.5% sensitivity in samples taken 14 days after a PCR-confirmed infection. The importance of specificity and sensitivity of a particular test will be dependent on its purpose and disease prevalence within a given population.
About Roche Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people's lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalized healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. For more information, please visit www.roche.com.
Hogan Pharmacy Ready to Implement Provincial Government Call for Medication Safety Technology for Long-Term Care Now
Ready to Provide Automated Dispensing Cabinets and Registered Pharmacy Technicians Today to All Ontario Long Term Care Homes, Keeping Insulin & Fentanyl Locked Away
Hogan Pharmacy Partners Ltd. 704-B Eagle Street North, Cambridge, ON hoganpharmacypartners.com 1-888-223-1011
CAMBRIDGE, ON, Aug. 4, 2020 /CNW/ - Hogan Pharmacy Partners applauds Premier Ford and Minister Fullerton's announcement of the Medication Safety Technology Program to make significant improvements to the Long-Term Care Pharmacy System and to the way that Ontario's Seniors receive their medications. Hogan Pharmacy Partners has been sharing its medication safety technologies with the Ministry since 2018 to support Ontario in its vision to improve the quality of life and care for all of Ontario's most valuable elders.
"Most Ontario Nursing Homes rely on already tragically overworked Nurses to manage all of the medications in Nursing Homes," says Hogan's Vice President, Becky Agar. "And potentially fatal medications like insulin and fentanyl are literally still being stored in plastic lockboxes with a hardware-store padlock. It's no surprise that narcotics and insulin go missing in so many Nursing Homes every day in Ontario."
"We've already heard from the Wettlaufer Inquiry and the Canadian Armed Forces Report during their stay in Ontario Homes during COVID-19 that our Nurses need the support of Profiled Dispensing Cabinets to make medication administration safer for Residents and easier for them to give high-risk medications and to protect Residents from accidental harm and those who wish to do them harm on purpose."
Becky Agar continues, "When Ontario Families start returning to visit their loved ones in Nursing Homes, they need to start asking direct questions now about how medications are being stored in the Home, and what their Nursing Home's plan is to bring in Profiled Dispensing Cabinets and 24-Hour Pharmacists to keep their loved ones safe as soon as possible."
Founded in 2015, Hogan Pharmacy Partners was the first Long-Term Care Pharmacy to use Automated Dispensing Cabinets and is still the ONLY Pharmacy that makes sure that these cabinets are tailored to specifically identify each individual Resident and their individual medication record. Hogan Pharmacy is also the first Long-Term Care Pharmacy to employ full-time Pharmacy Technicians in Long-Term Care Homes, working daily to support hard-working Nurses as they care for Ontario's Seniors. Recognized by Justice Gillese and the Long Term Care Inquiry in 2018 as a Leader in Medication Safety, our award-winning Pharmacist-Led Medication Reconciliation has been shown to help Ontario Nursing Home Residents take fewer medications and have an improved quality of life, and allows Long-Term Care Nurses to spend more time with their Residents, a cornerstone service that Hogan Pharmacy provides to all of our Partner Nursing Homes. Every Hogan-supplied medication is accessed only by fingerprint, with no missing insulin doses or runaway narcotics in a Hogan-run Nursing Home.
Ontario Long-Term Care Residents deserve the safest, most trusted medication systems in the Homes where they live. Hogan Pharmacy Partners again salutes the significant investment the Province is making to improve the lives of all Ontario Long-Term Care Residents.
SOURCE Hogan Pharmacy Partners Ltd.
Long-term maternal Viagra treatment worsens growth-restriction in baby sheep
Peer reviewed Experimental study Animals
UNDER STRICT EMBARGO UNTIL 01.00 GMT 5 AUGUST 2020
Not for publication or broadcast before this time
New research published today in The Journal of Physiology shows that giving sildenafil (Viagra), which cause blood vessels to dilate, impairs the fetus’ ability to redirect blood flow to essential organs in response to low levels of oxygen, impeding fetal growth. This study was conducted in an animal model of growth restriction where placental blood flow is restricted.
It is well accepted that in a fetus, in response to low levels of oxygen throughout the body (called hypoxia) blood flow is redirected to essential organs (such as the brain and heart) and away from non-essential organs, to help sustain life.
This new finding about giving pregnant sheep Viagra was especially important because while this study was being conducted, a large clinical study was investigating maternal sildenafil in pregnancies affected by fetal growth restriction as a potential treatment to improve fetal growth and correct impaired placental function by increasing blood flow.
This clinical study was halted early, following evidence that maternal Viagra treatment resulted in increased morbidity in babies. However, the mechanisms behind the increased morbidity was not understood.
Our study provides crucial insight into a potential mechanism underlying the increased morbidity. We show that prenatal sildenafil lowered levels of oxygen in the fetal blood, but despite this, the fetus did not respond by redirecting blood to essential organs. This finding may underlie the adverse outcomes observed clinically.
Viagra is a well-known drug that dilates blood vessels and its ability to increase blood flow to certain areas has been well described in other medical conditions. Therefore, the investigation into its potential for improving fetal growth by increasing placental blood flow, was warranted.
However, we show that Viagra can cross the placenta and have effects on the fetus. The results of our study highlighted the importance of thorough pre-clinical investigation in large animal models prior to the initiation of large clinical trials.
Our study replicated the impaired placental function that was observed clinically, in fetal sheep as a pre-clinical model. Using sheep as a model organism, we were able to implant monitoring equipment into these fetal sheep to monitor changes in both maternal and fetal blood flow and physiology in response to low oxygen levels in the blood and Viagra treatment.
A key difference between our study and the previously discussed clinical trials, and a limitation, is the way we delivered the Viagra. Clinical studies involved oral administration to the mother, whereas we delivered sildenafil intravenously, which may have resulted in different circulating levels of the drug in the blood. Additionally, while our study demonstrates the effects of sildenafil in a growth restricted fetus, we could not investigate the effect of sildenafil on a healthy fetus.
First author Ishmael Inocencio said:
“A key finding of our study was the unexpected exacerbation of growth restriction following Viagra treatment. This has important implications for the danger of administering this drug to pregnant women.”
The Journal of Physiology publishes advances in physiology which increase our understanding of how our bodies function in health and disease. http://jp.physoc.org
The Physiological Society brings together over 4,000 scientists from over 60 countries. The Society promotes physiology with the public and parliament alike. It supports physiologists by organising world-class conferences and offering grants for research and also publishes the latest developments in the field in its three leading scientific journals, The Journal of Physiology, Experimental Physiology and Physiological Reports. www.physoc.org
SCHOOL RE-OPENINGS: ONE PARENT'S DESPERATE PLEA Insights from the Front-Line of this Great Debate As the school year approaches, parents across the country now face the difficult decision on whether they will send their child back to school. We yearn for so much normal that we can’t fathom the start of school being anything other than normal. COVID-19 continues to surge in cities across the country leaving parents with a basket of impossible choices. But one Arizona Parent is speaking out with a desperate plea to both parents and leaders. "If our fundamental jobs as parents is to protect our child from harm, then we are about to fail in a monumental way. We are ultimately playing Russian Roulette with the safety of our kids, our family, our towns—and our country..." ...says Carew Papritz, an educational activist, author, and parent whose son is due back in school in just one week. According to Papritz, the decision to re-open schools must be made on facts, science, and statistics. In communities where COVID is surging, it is simply not safe unless testing is done every day. "We are the parents of 76 million students, and we need to use our amazing powers of influence and we need guidance and support from the leaders..." ..says Papritz. Our children are not businesses to open or close at will. They are not bowling alleys or bars, or hair salons or movie theaters that can be opened or closed depending on the whim of the virus. Our kids are our lives. They need us to stand up for them—for their health and safety—for their lives. They need school. They need teachers. They need to learn..Papritz is urging parents across the country to yield their parenting powers, speak out, demand answers from leaders, and be on the front-line for child safety.TALKING POINTS (FOR INTERVIEWS / ARTICLES):How to Yield your Parenting Power & Demand Answers One Arizona Parent's Desperate Plea Re-Opening Schools Based on Facts, Science, and StatisticsPhysical and Emotional Effects of Online vs. In-person Learning
ABOUT CAREW PAPRITZ:
Carew Papritz is an educational thought-leader, literacy advocate, and author of the multi-award-winning book, The Legacy Letters.Through his YouTube videos, including the I Love to Readseries andhisFirst-Ever Book Signings, and events such as creating National Thank You Letter Day and the World’s Largest Handwritten Thank You Letter, Papritz spreads the love of reading, learning, and civility to people of all ages. Papritz has made a global impact by being an advocate for literacy and teaching future generations about the importance of legacy. Papritz's writings have been published in a number of media outlets including, The Huffington Post, Reader's Digest, First Time Parent Magazine, and Inc. His most recent Op-ed comments on his time as a freelance photojournalist in the Los Angeles Riots: Why the Riots Again? The Power of Not Normal as Normal.FOR MORE INFORMATION VISIT: https://thelegacyletters.com
TRAIN IT RIGHT NEWSLETTER
Sign Up and get a free 7 day Train it Right HIIT Program!
According to Neuroscience expert Dr. Patrick Porter, mental clarity is crucial for productivity. "Increased stress and anxiety surrounding COVID-19 has understandably caused work productivity to plummet because your emotional state is directly connected to your ability to focus..."...says Dr. Porter, who has devoted his career to researching the brain and mental wellness. According to Dr. Porter, stress, anxiety, and fear elevate cortisol levels in the brain which interferes with memory making it impossible to concentrate on your work. Not only is this bad for employees who are stressed out and scrambling to make ends meet with growing to do lists - it is also bad for entire corporations and businesses as the decrease in productivity significantly impacts a company's bottom line. "Luckily, there are strategies you can do to improve mental clarity and reduce stress so you can beat distraction and focus..."...says Dr. Porter. One productivity-boosting strategy he recommends is to take a "time-out" every 75 to 90 minutes. While it may sound counterintuitive, many studies have shown a link between taking breaks and increased productivity. Stepping away from work for 10-15 minutes resets your brain, allows your mind to relax, and gets you in a clear headspace. Dr. Porter is also an advocate of restorative activities like exercising and meditating - both of which increase your ability to focus on tasks and remember information. Dr. Porter is sharing productivity-boosting tips for the American workforce. He has brain-based strategies and actionable advice people can use to reduce stress, beat distraction, and increase mental clarity, and focus. TALKING POINTS (FOR INTERVIEWS & ARTICLES):How to Focus in the Office Amid COVID Anxiety & StressTips to Improve Mental Clarity & Focus While Working at Home (& Distracted by Kids)Strategies to Survive Working From Home With Children How to Reframe Anxiety & Channel It Into Motivation & ProductivityFascinating Science Behind Stress, The Brain, & Productivity7 Ways to Stay Productive When You're StressedHow Sleep Impacts Productivity at WorkProductivity & The Pandemic: The Mental Health Impact of COVID-19 on Business & WorkHow Managers and Employers Can Help Their Team Stay Focused ABOUT DR. PATRICK PORTER:
Patrick K. Porter, Ph.D., is an award-winning author and speaker who has devoted his career to neuroscience and brainwave entrainment. As the creator of 
"If our fundamental jobs as parents is to protect our child from harm, then we are about to fail in a monumental way. We are ultimately playing Russian Roulette with the safety of our kids, our family, our towns—and our country..." ...says Carew Papritz, an educational activist, author, and parent whose son is due back in school in just one week. According to Papritz, the decision to re-open schools must be made on facts, science, and statistics. In communities where COVID is surging, it is simply not safe unless testing is done every day. "We are the parents of 76 million students, and we need to use our amazing powers of influence and we need guidance and support from the leaders..." ..says Papritz. Our children are not businesses to open or close at will. They are not bowling alleys or bars, or hair salons or movie theaters that can be opened or closed depending on the whim of the virus. Our kids are our lives. They need us to stand up for them—for their health and safety—for their lives. They need school. They need teachers. They need to learn..Papritz is urging parents across the country to yield their parenting powers, speak out, demand answers from leaders, and be on the front-line for child safety. TALKING POINTS (FOR INTERVIEWS / ARTICLES):How to Yield your Parenting Power & Demand Answers One Arizona Parent's Desperate Plea Re-Opening Schools Based on Facts, Science, and StatisticsPhysical and Emotional Effects of Online vs. In-person Learning 
